Investors File Securities Fraud Lawsuit Against GRAIL Over Trial Failures
A 50.55% collapse in share price has triggered a securities fraud class action against GRAIL, Inc., following revelations that the company's landmark NHS-Galleri cancer screening trial failed to meet its primary goals. Investors now have until August 4, 2026, to seek lead plaintiff status in the ongoing litigation.
The lawsuit, filed by Hagens Berman Sobol Shapiro LLP, alleges that GRAIL misled shareholders between May 13, 2025, and February 19, 2026. According to the complaint, senior executives repeatedly touted the trial’s three-year follow-up period as sufficient to prove a reduction in late-stage cancer diagnoses. Plaintiffs contend that the company selectively highlighted positive preliminary data while suppressing internal evidence that the study design was fundamentally inadequate to reach its endpoint.
On February 19, 2026, the company disclosed that the trial failed to demonstrate a statistically significant reduction in Stage III and IV cancers. GRAIL executives subsequently conceded that the follow-up period should have been longer. The market response was immediate: share prices plummeted from $101.53 to $50.21, wiping out $2.2 billion in market value in a single session. Reed Kathrein, the partner leading the investigation, stated the firm is now scrutinizing exactly when management realized the three-year timeline was insufficient for the study’s stated objectives.
Comments (0)
No comments yet. Be the first!